Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

84.03 +0.11 (+0.13%)
Streaming Delayed Price Updated: 1:15 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Which S&P500 stocks are moving before the opening bell on Tuesday?
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session. 
Via Chartmill
Merck Posts Q2 EPS Beat Revenue Slips
Via The Motley Fool
Merck’s (NYSE:MRK) Q2 Earnings Results: Revenue In Line With Expectations
Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was... 
Via StockStory
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results
From Merck & Co., Inc.
Via Business Wire
Earnings Scheduled For July 29, 2025
 
Via Benzinga
Merck & Co's Earnings Outlook
 
Via Benzinga
P/E Ratio Insights for Merck & Co
 
Via Benzinga
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever
If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%. 
Via The Motley Fool
Topics Lawsuit
After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact
GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion. 
Via Benzinga
How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings
Merck offers a quarterly dividend amount of 81 cents per share. To receive $500 monthly, here's what you do. 
Via Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
These big pharma stocks arguably aren't receiving the respect they deserve. 
Via The Motley Fool
Topics Intellectual Property
Merck Commits To Veeva’s Vault CRM, Draws Wall Street Cheer: Retail’s Not Enthusiastic
Via Stocktwits
Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided
Via Stocktwits
What To Expect From Merck’s (MRK) Q2 Earnings
Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Tuesday before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants. 
Via Benzinga
Topics Artificial Intelligence ETFs
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma
AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles. 
Via Benzinga
Merck & Co. Inc. (NYSE:MRK): A Strong Value Investment with Undervalued Potential
Merck & Co. (MRK) is a top value stock with strong fundamentals—undervalued P/E, high profitability, stable finances, and steady growth, making it a smart pick for value investors. 
Via Chartmill
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst. 
Via Investor's Business Daily
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment. 
Via Investor's Business Daily
Merck Announces Fourth-Quarter 2025 Dividend
From Merck & Co., Inc.
Via Business Wire
MERCK & CO. INC. (NYSE:MRK) – A Quality Stock with Strong Fundamentals
MERCK & CO. INC. (NYSE:MRK) is a high-quality stock with strong profitability, efficient capital use, and a reliable dividend, making it a solid pick for long-term investors. 
Via Chartmill
Does This Move Make Merck Stock a Buy?
Via The Motley Fool
Topics Intellectual Property
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?
Via The Motley Fool
Topics Economy Intellectual Property
Want Decades of Passive Income? Buy This ETF and Hold It Forever
Via The Motley Fool
Topics ETFs Regulatory Compliance Stocks
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Got $200? 2 Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business
Via The Motley Fool
Topics Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
1 Dow Jones Stock to Target This Week and 2 to Avoid
While the Dow Jones (^DJI) represents industry leaders, not every stock in the index is a safe bet. Some are facing headwinds like declining demand, rising costs, or disruptive new competitors. 
Via StockStory
Topics Stocks
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.